Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 5/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5763676 | 1.00 | NOS1 (0.40) | NOS1NOS3NOS2LTA4HSLC1A2 | |
| SCHEMBL17449764 | 1.00 | NOS1 (0.40) | NOS1NOS3NOS2LTA4HSLC1A2 | |
| SCHEMBL67349 | 1.00 | NOS1 (0.40) | NOS1NOS3NOS2LTA4HSLC1A2 | |
| Hydrochloric Acid SCHEMBL311215 | 0.98 | NOS1 (0.39) | NOS1NOS3NOS2LTA4HSLC1A2 | |
| Bromide SCHEMBL8760868 | 0.98 | NOS1 (0.39) | NOS1NOS3NOS2LTA4HSLC1A2 | |
| Hydrochloric Acid SCHEMBL952472 | 0.98 | NOS1 (0.39) | NOS1NOS3NOS2LTA4HSLC1A2 | |
| SCHEMBL3294154 | 0.89 | NOS1 (0.42) | NOS1NOS3NOS2LTA4HSLC1A2 | |
| SCHEMBL5967210 | 0.88 | SLC1A2 (0.46) | NOS1NOS3NOS2SLC1A2SLC1A1 | |
| SCHEMBL7266730 | 0.88 | SLC1A2 (0.46) | NOS1NOS3NOS2SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL5967206 | 0.86 | SLC1A2 (0.44) | NOS1LTA4HSLC1A2SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118956991-B | Synthesis method of chiral amine | 天津凯莱英生物科技有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-118956991-A | Synthesis method of chiral amine | 天津凯莱英生物科技有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-122055354-A | Lipid compounds and related compositions and uses | 波西达治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-118956991-B | Synthesis method of chiral amine | 天津凯莱英生物科技有限公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2025049925-A2 | LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES | POSEIDA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-118956991-A | Synthesis method of chiral amine | 天津凯莱英生物科技有限公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-3530290-A1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-08-28 | — | — | EP | disclosed |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2019-01-08 | — | — | US | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-9328112-B2 | Tetracyclic CDK9 kinase inhibitors | ABBVIE INC. (US) | 2016-05-03 | — | — | US | disclosed |
| CN-105392780-A | Pathway specific assays for predicting irritable bowel syndrome diagnosis | NESTEC SA | 2016-03-09 | — | — | CN | disclosed |
| CN-101541800-A | Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer | CHROMA THERAPEUTICS LTD (GB) | 2009-09-23 | — | — | CN | disclosed |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2007-08-30 | — | — | US | disclosed |
| CN-1305846-C | Urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2007-03-21 | — | — | CN | disclosed |
| EP-1040103-B1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2007-03-14 | — | — | EP | disclosed |
| CN-1914225-A | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2007-02-14 | — | — | CN | disclosed |
| EP-1713823-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005073195-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
| US-6268354-B1 | Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-31 | — | — | US | disclosed |
| CN-1282326-A | Anilide derivative, process for producing the same, and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | NOS1 3193/4885NOS3 1394/4885NOS2 3787/4885 |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | HPN, CPN1, PRSS1 | NOS1 2714/4885NOS3 1025/4885NOS2 3297/4885 |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | HPN, CPN1, PRSS1 | NOS1 3193/4885NOS3 1394/4885NOS2 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.